Study,Year,Data source,ID: CRS,Char: Methods,Char: Participants,Char: Interventions,Char: Outcomes,Char: Notes
Abrahamsson 2007,2007,PUB,2621274,"<p>Double-blind, randomised, placebo-controlled trial.</p>","<p><b>Inclusion criteria:</b> families with allergic disease (1 or more family members with eczema, asthma, gastrointestinal allergy, allergic urticaria, or allergic rhinoconjunctivitis) recruited at antenatal clinics.</p>
<p><br><b>Exclusion criteria: </b>mother reporting peanut allergy. Infants admitted to neonatal unit in first week. Insufficient compliance led to exclusion of participants from the study.</p>","<p><b>Treatment (n = 117): </b>Lactobacillus reuteri 1x10<sup>8</sup> cfu daily (freeze-dried, suspended in coconut and peanut oil) given to mother for 4 weeks before delivery, mother and baby daily for 12 months after delivery.</p>
<p><br><b>Control (n = 115): </b>placebo (same oil).<br>
 Co-interventions: infants breast-fed. When weaned, given whey hydrolysate formula to 6 months (both groups).</p>
<p>Mothers were encouraged to breastfeed. At weaning, babies were offered a hypoallergenic whey hydrolysate until 6 months of age.&nbsp;</p>","<p><b>Primary outcomes:</b> eczema and sensitisation in first 2 years conducted by a paediatrician. SPTs were performed at 6, 12 and 24 months of age. Circulating IgE antibodies to common allergens were assessed at 6, 12 and 24 months of age. Follow up study at 7-years, allergic disease and skin prick test reactivity were assessed.Follow up assessment by research nurse and structured telephone interview up to 2 years.&nbsp;</p>
<p><br><b>Other outcomes:</b> symptoms of allergic disease, adverse events, infections, use of antibiotics and possible confounding factors and inspection of the skin. SCORAD index was used to assess the severity of eczema. Records from primary care units, private paediatricians and the paedatric clinics were examined if parents reported that child had been examined by physician. Outcomes of the study are assessed as per diagnostic criteria described in the study.<br>
 &nbsp;</p>
<p><b>Definitions: </b>eczema is physician confirmed. SCORAD score used. Defined as pruritic, chronic or chronically relapsing non-infectious dermatitis with typical features and distribution.</p>
<p>Gastrointestinal allergy required vomiting, diarrhoea, or systemic reaction after ingestion of a potentially allergenic food and a confirmation by challenge, unless there was a clear history of a severe systemic reaction.&nbsp;<br>
 Infants were regarded as sensitised if they had at least 1 positive SPT or detectable circulating allergen specific-IgE antibodies, or both.<br>
 Allergic disease assessed at 7 years of age (±3 months) included asthma, allergic rhinoconjunctivitis (ARC), allergic urticaria and eczema.&nbsp;</p>
<p><br>
 Asthma diagnosis required at least 1 of following 2 criteria:</p>
<ul>
 <li>doctor diagnosis and asthma symptoms or medication, or both, during the last 12 months; and</li>
 <li>wheeze or nocturnal cough and a positive reversibility test or pathological FE<sub>NO</sub> value, or both.&nbsp;</li>
</ul>
<p>Diagnosis of ARC based on standard ISAAC question and required watery discharge at least twice in contact with the same allergen and no sign of infection.<br>
 Had symptoms of or has been treated for the actual allergic disease during the last 12 months, or both.&nbsp;</p>","<p><b>Sponsor: </b>Grants from BioGaia AB, Stockholm, Sweden, the Ekhaga Foundation, the Heart and Lung foundation, the Research Council for the South-East Sweden (grant No. F2000-106), the Swedish Asthma and Allergy Association, the Swedish Research Council and the University Hospital of Linköping, Sweden.</p>
<p>2011 update: Additional publications; no additional allergy or food hypersensitivity data. 2023 update: Additional publications; addition of 7-year follow up data on allergic disease and skin prick test reactivity. Allergic disease at (quote:) ""2 years and/or 7 years"" included in analysis under childhood incidence. Prevalence of allergic disease (quote:) ""between six and 7 yr of age"" included in analysis under childhood prevalence.&nbsp;</p>
<p><b>Declaration of interests:</b> B. Björkstén has consulting arrangements with BioGala Inc. The rest of authors have declared that they have no conflict of interest.</p>"
Allen 2014,2014,PUB,23696192,"<p>Randomised, double-blind, placebo-controlled, parallel group trial.</p>","<p><b>Inclusion criteria: </b>women 16 years or older with a normal singleton pregnancy. The intention was to recruit infants at high risk of developing atopy; however, sufficient details of atopy in first-degree relatives were often difficult to obtain at recruitment. Therefore, infants with and without increased risk of atopy were recruited.</p>
<p><b>Exclusion criteria: </b>any known adverse condition affecting the woman, foetus, or the likely outcome of the pregnancy; if a member of the foetus’s sibship or household was already recruited to the study; or if the woman was unwilling to discontinue use of other live bacterial dietary supplements</p>","<p><b>Treatment (n = 220): </b>probiotic supplement Lactobacillus salivarius LS33 6.25x10<sup>9</sup> cfu, Lactobacillus paracasei CUL08 1.25x10<sup>9</sup> cfu, Bifidobacterium infantis Bi07 1.25x10<sup>9</sup> cfu and Bifidobacterium bifidum CUL20 1.25 x 10<sup>9</sup> cfu.&nbsp;</p>
<p><br><b>Control (n = 234): </b>maltodextrin 100 mg.<br>
 Mother from 36 weeks' gestation until delivery. Infant from birth to 6 months.<br>
 Weeks (median (range)) exclusively breast-fed, treatment group (n = 167): 2 (0 – 8); control (n = 161): 3 (0 – 8).</p>
<p>Both arms received 1 capsule daily from 36 weeks' gestation until delivery. Infants received the same capsules as their mother 1x daily from birth to age 6 months. Contents of the capsule were sprinkled directly into the infant's open mouth or mixed with expressed breast milk or formula feed.</p>","<p><b>Primary outcomes</b>: the cumulative frequency of diagnosed eczema (assessed by the SCORAD system) at the 2-year follow up (reported by a parent to have been diagnosed by a clinician or assessed by a study clinician or trained research personnel). Changes to symptoms and adverse effects related to atopy.</p>
<p><b>Other outcomes:</b> responses to SPTs, atopic eczema defined as eczema with 1 or more positive SPTs, eczema of any duration and whether or not diagnosed by health professional, severity of eczema, treatment with topical steroid preparations, respiratory symptoms with asthma and allergic rhinitis and reported food allergies.</p>
<p><b>Definition:</b> eczema defined as an itchy rash affecting the face, scalp or extensor surfaces of the limbs in infants and flexures in older children and of duration ≥ 4 weeks and with ≥ 1 exacerbation by age 24 months.</p>","<p><b>Sponsor:</b> knowledge exploitation fund, Collaborative Industrial Research Project number: HE 09 COL 1002, Welsh Assembly Government (UK)</p>
<p><b>Declaration of interests: </b>SFP is a director of Cultech. IG reports grants from Cultect UK, during the conduct of the study. SJA reports a grant from Yakult UK outside the submitted work. The remaining authors declared that they have no competing interests.&nbsp;</p>"
Cabana 2007,2007,MIX,22958592,"<p>Randomised, double-blind, placebo-controlled trial.</p>","<p><b>Inclusion criteria: </b>newborns at increased risk of atopy, defined as at least 1 biological parent with a history of asthma. Parents had to speak and read English or Spanish. Recruitment occurred during the third trimester of pregnancy, with random assignment of infants occurring within 4 days after birth.</p>
<p><b>Exclusion criteria: </b>any major congenital birth deformities, acute illness at enrolment (within 4 days after the newborn infant's birth), or any condition affecting food intake or metabolism.</p>","<p><b>Treatment (n = 92):</b> daily capsule of 10 billion colony-forming units of LGG and 225 mg of inulin for the first 6 months of life.</p>
<p><b>Control (n = 92):</b> daily capsule of 325 mg of inulin for the first 6 months of life.</p>
<p>The intervention started within the first 4 days of life. The supplement was dissolved in 2mL of pumped breast milk, infant formula or sterile water and fed to the infant. To promote breast-feeding, all participating families were encouraged to use breast-feeding and were provided with a breast pump.</p>","<p><b>Primary outcome:</b> incidence of eczema within 2 years of birth. This was assessed at 5 timepoints (1, 2, 6, 12 and 24 months) by a clinical examination performed by a study clinician.</p>
<p><b>Other outcomes:</b> incidences of asthma and allergic rhinitis within 5 years of birth. This was assessed by a parental telephone survey conducted monthly during the first year of life, then semiannually thereafter. Questions included: any diagnoses of asthma, allergic rhinitis or eczema by a health care professional.</p>
<p><b>Definition:</b> the diagnosis of asthma is difficult to establish at a young age, therefore the study focusses on early markers of asthma including a history of frequent wheezing, wheezing without colds, atopic dermatitis and rhinitis using a standard history assessment developed by&nbsp;Castro-Rodriguez 2000.</p>","<p><b>Sponsor: </b>funded by the Clinical and Translational Science Institute (UL1 RR024131) at the University of California, San Francisco, and by the National Institutes of<br>
 Health, HL 080074. Funded by the National Institutes of Health (NIH).Parental telephone survey-Additional question regarding feeding practices (breast milk only/formula only/combination/other/does not apply) were asked to assess for potential confounding.</p>
<p><b>Declaration of interests: </b>Dr Lynch was a co-founder and served on the board of directors for Siolta Therapeutics, a microbiome therapeutics company. Dr Cabana has served as a paid scientific consultant to BioGaia, Mead Johnson Nutrition, Nestle, and Wyeth (unrelated to the study), has received grant funding from Nestec (unrelated to study), and has served on the Merck Speakers Bureau for topics focused on medication adherence (unrelated to study); and other authors have indicated they have no potential conflicts of interest to disclose.</p>"
Dissanayake 2018,2018,PUB,22958408,"<p>&nbsp; 2 × 2 factorial, randomised, non-treatment controlled trial.</p>","<p><b>Inclusion criteria:</b> families who attended the antenatal clinic were recruited into the study. Following delivery, the babies were recruited if they were born at term and written informed consent was available from parent(s)/guardian. A family history of atopy was not required for inclusion.&nbsp;</p>
<p><b>Exclusion criteria: </b>infants born pre-term, experience complications due to severe underlying disease were excluded from the study. HBV or HIV positivity of mother at the time of birth or any other inappropriate status as judged by the physician.&nbsp;</p>","<p><b>Synbiotic and skincare (n = 137): </b>combination of 0.5 g (7 × 10<sup>9</sup> CFU/g) of <i>Bifidobacterium bifidum</i>OLB6378 (Meiji Holdings Co. Ltd., Japan) combined with 0.5 g of fructo-oligosaccharides (Meiji Food Materia Co., Ltd., Japan) twice a day and Locobase® REPAIR Cream (Daiichi Sankyo, Japan) which contains ceramide, cholesterol, and free fatty acids 2 - 3 times a day. Intervention was carried out from birth to 6 months of age.&nbsp;</p>
<p><b>Synbiotic only (n = 137): </b>combination of 0.5 g (7 × 10<sup>9</sup> CFU/g) of <i>Bifidobacterium bifidum</i>OLB6378 (Meiji Holdings Co. Ltd., Japan) combined with 0.5 g of fructo-oligosaccharides (Meiji Food Materia Co., Ltd., Japan) 2x a day from birth to 6 months of age.&nbsp;</p>
<p><b>Skincare only (n = 138):</b> locobase® REPAIR Cream (Daiichi Sankyo, Japan) which contains ceramide, cholesterol, and free fatty acids 2 - 3 times a day from birth to 6 months.</p>
<p><b>Control (n = 137): </b>the control group did not receive any synbiotics. The no treatment group was not prevented from applying emollients due to ethical reasons.&nbsp;</p>","<p><b>Primary outcome:</b> development of atopic dermatitis by 1 year of age.&nbsp;</p>
<p><b>Secondary outcome:</b> prevalence of food allergy. Sensitisation to food or inhalant allergens or both. EASI score examined by a paediatrician.&nbsp;</p>
<p><b>Definitions:</b> atopic dermatitis was diagnosed according to the criteria of the Japanese Dermatological Association (Katayama 2017), and using the UK Working Party's Diagnostic Criteria (William 1994), included in the questionnaire at 1 year. Defined as itchy rash lasting 2 or more months was reported in the questionnaires returned at 1, 6, and 9 months and 1 year of the baby’s age.&nbsp;</p>
<p>Food allergy reported in the questionnaire at 1 year. Sensitisation to food or inhalant allergens in total, or both, and allergen-specific IgE levels in blood sampled at 9 months of age.</p>","<p><b>Sponsor: </b>supported by the Environmental Restoration and Conservation Agency of Japan in fiscal years 2014 - 2016. Grants from the Japan Agency for Medical Research and Development.</p>
<p>The incidence of AD at 1 year according to the UKWP diagnostic criteria has been used for analysis in this review.</p>
<p><b>Declaration of interest: </b>no conflicts of interest to disclose</p>"
Hascoët 2011,2011,PUB,22958412,"<p>Randomised, double-blind, controlled trial.</p>","<p><b>Inclusion criteria: </b>healthy, full-term infants whose mothers had chosen to feed their infants exclusively with either breast milk or with formula starting from day 7 of birth until they were 4 months old. Infants had to be ≤ 7 days old at enrollment, weigh between 2500 and 4500 g, and be singletons.&nbsp;</p>
<p><b>Exclusion criteria:</b> congenital illnesses or malformations that could affect normal growth; significant prenatal or postnatal disease or both; been rehospitalised for more than 2 days in the first 14 days of life (with the exception of infants that were rehospitalised because of jaundice); received antibiotics prenatally, at the time of enrollment, or during the 5 days preceding enrollment; received probiotic- or prebiotic-containing formulas at the time of enrollment. Caregivers who were not expected to comply with the study requirements. Infants participating in a different study were excluded.</p>","<p><b>Study formula group (n = 39): </b>study formula with low protein and phosphate content, high lactose and contained predominantly whey protein was given to infants from birth to 4 months of age.&nbsp;</p>
<p><b>Study formula + BL999 (n = 40): </b>study formula with low protein and phosphate content, high lactose and contained predominantly whey protein supplemented with 2 × 10<sup>7</sup> colony-forming units (CFU)/g of <i>B longum</i>, strain BL999 (ATCC: BAA-999 designation BB536, Morinaga, Japan; NCC3001) was given to infants from birth to 4 months of age.&nbsp;</p>
<p><b>Control formula (n = 38):</b> control formula was given to infants from birth to 4 months of age.&nbsp;</p>
<p>Breast-fed (n = 73): infants exclusively breastfed from birth to 4 months of age.&nbsp;</p>","<p><b>Primary outcome:</b> bifidobacterial counts at the 2-month visit.&nbsp;</p>
<p><b>Secondary outcomes: </b>non-<i>Bifidobacteria</i> bacterial counts, weight, length, head circumference, digestive tolerance, stool IgA, and the occurrence of adverse events.&nbsp;</p>
<p><b>Definitions:</b> adverse events were defined as illnesses or signs and symptoms of illnesses that occurred or worsened during the course of the study. Specific definitions for allergy-skin problems not included.&nbsp;</p>","<p><b>Sponsor:</b> Nestlé, Konolfingen, Switzerland was the sponsor of the study and also manufactured the formulas.&nbsp;</p>
<p>Only infants in the study formula group and study formula + BL999 group have been included for analysis in this review. (Quote:) ""Allergy-skin problems"" data points included in the analysis as eczema.</p>
<p><b>Declaration of interest:</b> PGS is an employee of Nestlé Nutrition, Nestec Ltd. The other authors reported no conflicts of interest.</p>"
Kalliomaki 2001,2001,PUB,24344284,"<p>Randomised, double-blind, placebo-controlled trial.</p>","<p><b>Inclusion criteria: </b>family history of atopic disease: ≥ 1 family member (mother, father, or older sibling) with atopic eczema, allergic rhinitis, or asthma. Families were recruited in antenatal clinics.<br><b>Exclusion criteria:</b> none reported.</p>","<p><b>Treatment (n = 77): </b>Lactobacillus rhamnosus GG 1 x 10<sup>10</sup> cfu prenatally to mothers and postnatally whilst breastfeeding up to 6 months; if not breast-fed given to infants mixed with water on spoon.</p>
<p><br><b>Control (n = 82): </b>placebo (microcrystalline cellulose).</p>
<p>Mean time exclusive and total time of breastfeeding children given placebo 2 to 7 months and 6·4 months, respectively, and those on Lactobacillus GG 3·0 months and 7·2 months, respectively.</p>","<p><b>Primary outcomes:</b> atopic disease at 2 and 4 years.</p>
<p><b>Other outcomes:</b> blinded physician assessment for atopy.</p>
<p><b>Definitions: </b>eczema: pruritis, facial or extensor involvement, or both, and chronic relapsing course (for 1 month or longer at the 24-month visit and on at least 1 &nbsp;previous visit. The SCORAD index used to assess eczema severity.&nbsp;<br>
 Allergic rhinitis: most days 2 or more of: nasal discharge, blockage, sneezing, and itching.<br>
 Asthma: based on an algorithm created by an international paediatric asthma consensus group. Diagnosed if infant had chronic or recurrent cough, wheeze or shortness of breath, or both, suggestive of asthma, and if other diagnoses were excluded and trial antiasthma treatment was effective.<br>
 Sensitisation measured by: skin-prick tests at 6, 12, and 24 months; and total and specific IgE assays on cord blood and at 3, 12, and 24 months.</p>
<p>4 years reported prevalence of eczema, asthma, allergic rhinitis (DBPCFC).</p>
<p>7 years reported cumulative incidence of eczema and prevalence of allergic rhinitis and asthma. Cumulative incidence eczema calculated from percentages reported.</p>","<p><b>Sponsor: </b>Finnish Foundation for Paediatric Research, the National Technology Agency of Finland, and the Allergy Research Foundation in Finland. 2023 update:&nbsp; Additional publications; addition of 4-year and 7-year follow-up data on allergic disease. Allergic disease persisted up to the age of 4 years included in analysis under childhood incidence. Skin prick test reactivity and allergic disease at 7-years of age included in analysis under childhood prevalence.</p>
<p><b>Declaration of interests:</b> not reported.</p>"
Kim 2010,2010,PUB,2621297,"<p>Randomised, double-blind, placebo-controlled trial.</p>","<p><b>Inclusion criteria: </b>pregnant women with a family history of allergic diseases. A family history of allergic diseases defined as:</p>
<ul>
 <li>at least 1 &nbsp;parent or older sibling of the foetus had eczema, as confirmed by a paediatric allergist; or</li>
 <li>1 of the parents diagnosed with asthma or allergic rhinitis, or both, by a physician, showing house dust mite-specific IgE &gt; 1.0 kU/L by CAP-FEIA immunoassay.</li>
</ul>
<p><b>Exclusion criteria:</b></p>
<ul>
 <li>premature babies delivered &lt; 36 weeks of gestation;</li>
 <li>infants with immune deficiency disease, necrotising enterocolitis, or congenital disorders; or</li>
 <li>those requiring anticancer treatment or a central venous catheter.</li>
</ul>","<p><b>Treatment (n = 57): </b>mothers in the probiotic group took a mixture of Bifidobacterium bifidum BGN4 [1.6 x 10<sup>9</sup> cfu], Bifidobacterium lactis AD011 (1.6 x 10<sup>9</sup> cfu), and Lactobacillus acidophilus AD031 (1.6 x 10<sup>9</sup> cfu) in 0.72 g of maltodextrin and 0.8 g of alpha-corn (Bifido Inc., Hongchungun, Korea) once daily from 8 weeks before the expected delivery to 3 months after delivery. Infants were fed the same powder dissolved in breast milk, infant formula, or sterile water from 4 to 6 months of age.</p>
<p><b>Control (n = 55): </b>mothers and infants in the placebo group took maltodextrin and alpha-corn without probiotic bacteria.</p>
<p>Mean duration exclusive breastfeeding probiotic group 5.97 months and control group 5.26 months.</p>","<p><b>Primary outcomes: </b>eczema and sensitisation against common food allergens. Infants were followed up to 1 year of age, involving examinations at 3, 6, and 12 months to assess the occurrence of eczema. Venous blood was obtained at 12 months to measure total IgE and specific IgE against common food allergens</p>
<p><b>Other outcomes:</b> clinical histories such as gestational age, birth weight, caesarean section delivery, mothers age, duration of breastfeeding, diet, fever (‡ 38.5C), respiratory tract infection, hospitalisation, acute gastroenteritis, and use of antibiotics.&nbsp;</p>
<p><br><b>Definitions:</b></p>
<p>Diagnosis of eczema was confirmed when the skin lesions met the criteria of Hanifin and Rajka (Hanifin 1980).<br>
 The severity of eczema was determined using the 'Six Area Six Sign in Atopic dermatitis (SASSAD) score'.<br>
 12 months total IgE and specific IgE against common food allergens (egg white, cow's milk, wheat, peanut, soybean, and buckwheat) using CAP-FEIA (Pharmacia, Uppsala, Sweden). Antigen-specific IgE levels &gt; 0.35 kU/L were considered positive. Probable egg allergy defined when the egg white-specific IgE level ≻ 2 kU/L. IgE associated eczema reported. However, antigen-specific results not reported for symptomatic infants.</p>","<p><b>Sponsor:</b> no commercial sponsor reported. Supported by grants (A060546 and A080664) from the Ministry for Health, Welfare and Family Affairs, Republic of Korea.</p>
<p><b>Declaration of interests: </b>not reported.</p>"
Kopp 2008,2008,PUB,2621304,"<p>Double-blind, randomised, placebo-controlled prospective trial.</p>","<p><b>Inclusion criteria: </b>pregnant women with:</p>
<ul>
 <li>an uneventful pregnancy;</li>
 <li>absence of underlying chronic disease; and</li>
 <li>a family history of atopic disease: 1 family member (mother, father, or older sibling) with AD, allergic rhinitis, or asthma and a confirmed allergic sensitisation against an inhalant allergen.</li>
</ul>
<p><b>Exclusion critiera</b>: none stated.</p>","<p><b>Treatment (n = 54):</b> L. rhamnosus GG (ATCC 53103) containing 5 x 10<sup>9</sup> cfu daily for 4 – 6 weeks before expected delivery. Capsules taken post-natally for 6 months. Directly after delivery, breastfeeding mothers took the capsules; otherwise, children received the agents (n = 2 in the LGG group, n = 3 in the placebo group). After 3 months, capsules were given only to the neonates.</p>
<p><b>Control (n = 51): </b>placebo (microcrystalline cellulose).</p>
<p>Duration of breastfeeding: median treatment 9 months, control 8 months.</p>","<p><b>Primary outcome:</b> prevention of atopic diseases during the first 2 years of life.</p>
<p><b>Other outcomes:</b> severity of atopic dermatitis, the cumulative incidence of atopic dermatitis, the incidence of recurrent (5 episodes) wheezing bronchitis, total immunoglobulin E (IgE) and the number of children with sensitisation to an inhalant allergen at the age of 2 years.</p>
<p><br><b>Definitions: </b>questionnaires and blinded physician examination. Physicians underwent standardised training program.<br>
 Eczema confirmed by pruritus, facial or extensor involvement, or both, and chronic relapsing course by using United Kingdom Working Party criteria (William 1994). The criterion (quote:) “chronic relapsing course” fulfilled if child had eczema for 1 month. The severity scoring of atopic dermatitis (Scoring Atopic Dermatitis Index) was used to assess eczema severity.<br>
 Skin prick tests, sensitisation to inhalant allergens and total IgE performed at 2 years reported for all infants.</p>","<p><b>Sponsor: </b>supported by the University of Freiburg and by Infectopharm, Heppenheim, Germany.</p>
<p><b>Declaration: </b>not reported.</p>"
Kukkonen 2006,2006,PUB,22958420,"<p>Randomised, double-blind, placebo-controlled study.</p>","<p><b>Inclusion criteria: </b>pregnant women with at least 1 parent of the unborn child had a physician-diagnosed allergic disease.<br><b>Exclusion criteria:</b> infants born &lt; 37 weeks' gestation, infants with major malformations, and B-twins.</p>","<p><b>Treatment (n = 610):</b> mothers took 1 capsule for 2 - 4 weeks before delivery containing Lactobacillus rhamnosus GG (ATCC 53103), 5 x 10<sup>9</sup> cfu; L rhamnosus LC705 (DSM 7061), 5 x 10<sup>9</sup> cfu; Bifidobacterium breve Bb99 (DSM 13692), 2 x 10<sup>8</sup> cfu; and Propionibacterium freudenreichii ssp. shermanii JS (DSM 7076), 2 x 10<sup>9</sup> cfu. Their newborn infants received 1 opened capsule containing the same probiotic mixed with 20 drops of sugar syrup containing 0.8 g of galacto-oligosaccharides once daily for 6 months after birth.<br><b>Control (n = 613): </b>placebo group mothers and infants took capsules containing microcrystalline cellulose, and infants received sugar syrup without galacto-oligosaccharides.</p>
<p><br>
 Exclusive breast-fed treatment group 2.6 months, control group 2.4 months. Standard adapted cow’s milk–based formula replaced breast milk when breast-feeding was insufficient. The use of hypoallergenic formula was restricted to infants allergic to cow’s milk.</p>","<p><b>Primary outcomes: </b>any allergic disease (food allergy, eczema, asthma, and allergic rhinitis) and IgE-associated (atopic) disease at 2 years.<br><b>Other outcomes:</b> eczema and sensitisation. Physician assessment at 3, 6, 24 months and 5 years. At 10 years parents completed questionnaires based on the ISAAC study. At 13 years, follow-up questionnaire was completed.</p>
<p><b>Definitions</b><br>
 Food allergy diagnosed with an open food challenge.<br>
 Eczema: according to the UK Working Party’s criteria (an itchy skin condition plus ≥ 3 of atopic disease in the family, dry skin during the last year, history of eczema, or visible eczema involving typical sites), (William 1994).<br>
 Atopic eczema: if IgE associated.<br>
 Severity of eczema evaluated using SCORAD score.<br>
 Asthma: 2 or more physician-diagnosed wheezing episodes accompanied by persistent cough or exercise-induced symptoms.</p>","<p><b>Sponsor: </b>grants from Valio Ltd; 2 authors employed by Valio Ltd.</p>
<p>2023 update: Inclusion of results from 5-year, 10-year, and 13-year follow-up studies. Childhood incidence analysis included results from 5-year follow-up. Childhood prevalence analysis included new onset of allergic disease and eczema diagnosed at age 5 - 10 years (ISAAC based). Adolescent allergic disease included allergic disease present at 13 years of age (12 mo ISAAC based). &nbsp;</p>
<p><b>Declaration of interests: </b>K. Kukkonen has received grant support from Valio Ltd. R. Korpela and T. Tuure are employed by Valio Ltd and by R&amp;D. T. Poussa has consultant arrangements with Valio Ltd. M. Kuitunen has received grant support from Valio Ltd. The rest of the authors have declared that they have no conflict of interest.</p>"
Lau 2012,2012,PUB,22958446,"<p>Blinded, randomised, placebo-controlled trial.</p>","<p><b>Inclusion criteria: </b>healthy newborns at term, birth weight of 2500 g or greater, 1 or 2 parents with atopic disease (atopic dermatitis, allergic rhinitis, or asthma), and informed consent. Families were informed of the study within the first week after the infant's birth through the obstetric department.</p>
<p><b>Exclusion criteria: </b>antibiotic treatment or other medication after birth, lymphocytopenia or thrombocytopenia, intensive care after birth, lack of German-language knowledge, and no informed consent.&nbsp;</p>","<p><b>Treatment (n = 303):</b> from week 5 until the end of month 7, infants had daily dose of 3 x 0.7mL of &nbsp;oral bacterial lysate (Pro-Symbioflor; SymbioPharm, Herborn, Germany) containing heat-killed non-pathogenic gram-negative E coli Symbio DSM 17252 and non-pathogenic gram-positive E faecalis Symbio DSM 16440 (1.5-4.5 3 107 bacteria/mL). 10 drops of the solution were administered to the infants with a spoon 3 times a day.&nbsp;</p>
<p><b>Control (n = 303):</b> placebo contained lactose monohydrate (4.9 mg/mL), sodium chloride (8.8 mg/mL), magnesium chloride (0.608 mg/ mL), calcium chloride (0.076 mg/mL), potassium chloride (0.133 mg/mL), magnesium sulfate (0.779 mg/mL), and aqua destillata (998.2 mg/mL).</p>","<p><b>Primary outcomes: </b>the prevalence of atopic dermatitis at the end of the prophylactic treatment period at 7 months of age.&nbsp;</p>
<p><b>Other outcomes: </b>specific serum IgE levels to 6 food allergens (cow's milk, hen's egg, wheat, peanut, soya, and cod fish) and 7 inhalant allergens (cat dander, dog dander, , Dermatophagoides pteronyssinus, birch, grass, mugwort, and Cladosporium herbarum; fx5, sx1; Phadia, Freiburg, Germany) and total IgE levels were measured at the ages of 5 and 31 weeks and 1, 2, and 3 years. Stool samples for analyses of gut flora.&nbsp;</p>
<p><b>Definitions: </b>Atopic dermatitis was clinically assessed by using a score according to the method of Hanifin and Rajka (Hanifin 1980) adapted for infants. Diagnosis for atopic dermatitis was made if infants showed a typical itchy rash at flexural/extensor sites, in the face, or both and dryness of the skin for more than 6 weeks.&nbsp;</p>","<p><b>Sponsor: </b>funding from SymbioPharm. SymbioPharm was involved in the study plan but had no influence on the analyses and interpretation of data.&nbsp;</p>
<p><b>Declaration of interests: </b>U. Wahn has received research support from SymbioPharm. The rest of the authors declared that they have no relevant conflicts of interest.</p>"
Morisset 2011,2011,PUB,22958450,"<p>Double-blind, randomised, control trial,</p>","<p><b>Inclusion criteria: </b>less than 6 months of pregnancy and family at risk of atopy defined as at least 2 atopic members including at least 1 of the parents (e.g. mother or father or at least 1 brother or sister).&nbsp;</p>
<p><b>Exclusion criteria: </b>children with known or suspected immune deficiency within family are excluded.&nbsp;</p>","<p><b>Treatment (n = 66): </b>infant formula made of milk fermented with B. breve C50 (4.2 x 10<sup>9</sup> bacteria per 100 g of powder formula) and S. thermophilus 065 (3.84 x 10<sup>7</sup> bacteria per 100 g of powder formula) and heated to kill ferments (heat-killed Bifidobacterium breve C50 and Streptococcus thermophilus 065 (HKBBST)). Formula was to be given every day, from birth to the end of breastfeeding.</p>
<p><b>Control (n = 63): </b>standard infant formula.&nbsp;</p>
<p>Co-intervention: &nbsp;from the 5th month of pregnancy, calcium supplement was included and avoid peanut, nut, egg and fermented milk products or prebiotic- or probiotic-containing food (commercially available milk was allowed).&nbsp;</p>
<p>Mothers who wished to breastfeed were encouraged to do so up to the 6th month after birth. From the 5th month of pregnancy, the mother was required to use calcium supplementation and avoid peanut, nut, egg and fermented milk products or pre-biotic- or probiotic-containing food.&nbsp;</p>","<p><b>Primary outcome:</b> incidence of cow's milk allergy and cow's milk sensitisation at 2 years.&nbsp;</p>
<p><b>Secondary outcome:</b> incidence of sensitisation or allergy to other allergens than cow's milk, or both, and the incidence of allergic symptoms during the study period.&nbsp;</p>
<p><b>Definitions: </b>children were considered allergic to cow's milk or to another food allergen, or both, when oral food challenge was positive. Children were considered sensitised to a food allergen in case of positive skin test (SPT or APT) or positive specific IgE independently of allergy-like symptoms.&nbsp;</p>","<p><b>Sponsor: </b>study was supported by Blédina, France (Danone group).</p>
<p><b>Declaration of interests: </b>C. Aubert-Jacquin was the Danone employee. M. Morisset, D. Moneret-Vautrin and C. Dupont have received honoraria or compensation with regards to the study, as an investigator, coordinator or expert, in relation with the time spent on the study. The authors declared no conflict of interest.</p>"
Niers 2009,2009,PUB,2621320,"<p>Double-blind, randomised, placebo-controlled trial.</p>","<p><b>Inclusion criteria: </b>pregnant women and their families were included at least 2 months before expected delivery (n = 156).</p>
<p>Families with a positive family history of allergic disease, i.e. atopic eczema, food allergy, asthma or allergic rhinitis in either the mother, or the father plus an older sibling with a history of allergic disease.</p>
<p><b>Exclusion criteria: </b>if their mother received antibiotic treatment during the last 2 weeks of pregnancy, child born before 37 weeks' gestation, children received antibiotic treatment in the first 2 weeks of life, if ingestion of the study product was difficult because of vomiting or feeding problems in general for longer than 3 weeks from birth, or if the children had other major medical problems.</p>","<p>Probiotic bacteria were prenatally administered to the pregnant mothers during the last 6 weeks of pregnancy and postnatally for 12 months to their offspring. The intervention was mixed with at least 10 ml of water, breast milk or infants' formula, depending on the choice of feeding by the parents, and ingested as a suspension.</p>
<p><b>Intervention group (n = 78): </b>once daily 3 x 10<sup>9</sup> cfu (1 x 10<sup>9</sup> cfu of each: B. bifidum W23, Bifidobacterium lactis W52 (previously classified as Bifidobacterium infantis), and Lc lactis W58) freeze-dried powder of the probiotic mixture.</p>
<p><b>Control group (n = 78):</b> placebo consisting of the carrier of the probiotic product, i.e. rice starch and maltodextrin. Breastfeeding treatment group 84%, control group 79%). Mean duration of breastfeeding treatment group 7.0 months, control group 7.2 months.</p>","<p><b>Primary outcome: </b>development of eczema during the first 2 years of life, and the initial effects on early microbial colonisation and immune responses. Symptoms indicative of food allergy, eczema, asthma and allergic rhinitis at age of 3, 12 and 24 months were evaluated.</p>
<p><b>Other outcome:</b> compliance and problems experienced with the daily administration of the study product. 6 year follow-up study included the preventative effect of probiotics on the prevalence of asthma, allergic rhinitis and eczema in these high risk children.&nbsp;</p>
<p><b>Definitions: </b>Parental reported eczema from diaries completed weekly.</p>
<p>Physician diagnosed eczema was defined as eczema reported by the parents and diagnosed as eczema by the family doctor or consulted physician.<br>
 Eczema was defined as non-infectious dermatitis with typical features (redness, dryness, oedema, oozing and itching (scratching)) and distribution.</p>
<p>Atopic eczema was defined as eczema plus sensitisation, i.e. detectable (&gt; 0.35 IU/ml) allergen specific IgE antibodies or a positive SPT.</p>
<p>6 year follow-up study included diagnosed allergic diseases from the treating family doctor, complete physical examinations, blood sampling and lung function testing.&nbsp;<br>
 Asthma was defined as at least 1 of the following 4 criteria: doctors diagnosed asthma active in the past 12 months, parental reported wheezing in the past 12 months, use of asthma medication in the past 12 months or an at least 9% reversibility in the forced expiratory volume in half a second (FEV 0.5) or in one second (FEV1).<br>
 Allergic rhinitis was defined according to the ARIA guidelines (Bousquet 2008).&nbsp;<br>
 Food allergy was defined as doctor diagnosed food allergy, combined with sensitisation to food allergens.&nbsp;<br>
 Eczema was defined according to the Williams UK Working Party's criteria (William 1994).</p>","<p><b>Sponsor: </b>declared independent study. 1 &nbsp;author employee of probiotic manufacturer (Winclove Bio Industries B.V., Amsterdam).&nbsp;</p>
<p>Outcomes of allergic disease at 6 years of age included in analysis under childhood incidence.</p>
<p><b>Declaration of interests:</b> HT was an employee of Winclove Bio Industries and the University Medical Centre Utrecht. All of the other authors declared that they had no conflict of interest.</p>"
Ortiz-Andrellucchi 2008,2008,PUB,2621322,"<p>Randomised, controlled, double-blind intervention study with parallel groups.</p>","<p><b>Inclusion criteria: </b>pregnant women aged 18 – 40 years in good general health, low obstetric risk with a normal delivery of a healthy baby.</p>
<p><b>Exclusion criteria:</b> participants &nbsp;with pre-existing conditions such as diabetes, hypertension, autoimmune diseases, asthma, allergy, renal diseases, hepatic diseases, antecedents of viral, bacterial or protozoan infection, multiple pregnancy, high-risk pregnancy, anaemia with Hb below 10·5% and those who smoked &gt; 10 cigarettes/d.</p>","<p><b>Treatment (n = 59):</b> milk fermented with L. casei DN-114001 consumed 3 times/day for 6 weeks, or</p>
<p><b>Control (n = 45):</b> placebo (killed L. casei).</p>
<p>Breastfed: probiotic group 92·6%, control group 81·6%.</p>
<p>The administration of the study products consisted of consumption 3 times per day during 6 weeks. Initiation of the fermented milk intake occurred on the day following the first extraction of blood and breast milk samples.</p>","<p><b>Primary outcomes:</b> to determine if probiotic modulated immune system in women who had recently delivered and were breast-feeding; role of probiotic intake on cytokines in maternal milk and on newborn health variables was also ascertained.</p>
<p><br><b>Other outcomes: </b>antropometry, respiratory episodes (cold, otitis, pharyngitis, laryngitis, bronchitis, pneumonia), gastrointestinal symptoms (oral candidiasis, regurgitation, diarrhoea, colic, constipation)</p>
<p><b>Definitions: </b>evaluated dermatitis and allergic episodes at 2 and 6 months. Definition of dermatitis (communication from author) does not meet review definition for eczema (dermatitis&nbsp;defined as erythematous&nbsp;lesions, with pruritus, presence of cradle cap, peeling and flaking (scaliness or desquamation).</p>
<p>Cow's milk allergy was confirmed by serological test and clinical diagnosis.</p>","<p><b>Sponsor: </b>Danone SA through research contract with the University Foundation of Las Palmas. One author worked for Danone S. A.</p>
<p><b>Declaration of interests:</b> J.C worked for Danone. None of the other authors had a conflict of interest.</p>"
Plummer 2020,2020,PUB,22958457,"<p>Double-blind, placebo-controlled randomised trial.</p>","<p><b>Inclusion criteria:</b> preterm infants both below 1500 g and less than 32 weeks' gestational age at birth.&nbsp;</p>
<p><b>Exclusion criteria:</b> infants suspected of or has major congenital anomalies, considered likely to die within 72 hours of birth as excluded. Babies of mothers who are already taking supplemental probiotics by capsule (not yogurt, etc) are excluded.&nbsp;</p>","<p><b>Treatment (n = 548)</b>: &nbsp;1 × 10<sup>9</sup> total organisms per 1.5 gm <i>Bifidobacterium infantis, Streptococcus thermophilus</i> and <i>Bifidobacterium lactis</i> (""ABC Dophilus Probiotic Powder for Infants<sup>®</sup>"", Solgar, USA) is given to infants from soon after the start of milk feeds until discharge home or term corrected, whichever comes first.&nbsp;</p>
<p><b>Control (n = 511)</b>: placebo. Maltodextrin powder contains 4 kcal/gram and is dairy free, gluten-free and suitable for vegans. The daily dose is 1.5 g of study powder, irrespective of infant's weight or postnatal age.</p>
<p><b>Substudy</b> in Victorian participants (n = 683) at 12 months' corrected age. Of the participants analysed in the substudy, probiotic group n = 127, placebo group n = 154.&nbsp;</p>
<p>The study intervention or placebo was given orally or via gastric tube once daily, unless the feed volume is less than 3 mL when 1 level ProPrems trial measuring spoon of powder is administered in 1.5 mL feed twice daily. Freshly expressed mother's breast milk is the feed of choice, followed by frozen breast milk, if fresh is not available. Banked breast milk is used when mother's milk is not available in centres with established protocols that use breast milk banking. Formula is used only when there is insufficient breast milk or if the mother chooses not to provide breast milk. Tube feeding is commenced as soon as possible in small and increasing amounts according to local protocols and the discretion of the treating neonatalist. Intravenous fluids and nutrition are used until approximately 120 ml/kg of milk is tolerated per 24-hour period.&nbsp;</p>","<p><b>Primary outcome:</b> incidence of at least 1 episode of definite late onset sepsis before 40 weeks' corrected age or discharge home.&nbsp;</p>
<p><b>Secondary outcomes:</b> incidence of clinically-suspected sepsis, NEC, mortality, duration of primary hospital admission, number of courses of antibiotics, number of days until full enteral feeds established&nbsp;</p>
<p><b>Substudy outcomes: </b>growth, infections, hospital admissions and antibiotic courses, cumulative incidence of allergic disease, immunological parameters, allergic sensitisation at 12 months.&nbsp;</p>
<p><b>Definitions:</b> eczema was defined as parent report of doctor diagnosis of eczema or fulfillment of the modified UK Working Party's Diagnostic Criteria (William 1994), for atopic dermatitis; a history of itchy skin in the preceeding 12 months, plus &nbsp;≥ 3 of the following visible dermatitis involving the skin creases extensor surfaces or &nbsp;cheeks, or both; a history of generally dry skin in the preceding 12 months; and a history of asthma or allergic rhinitis (or history of atopic disease in a first‐degree relative).&nbsp;</p>
<p>Atopic eczema was defined as eczema together with a positive SPT to 1 &nbsp;or more allergen.&nbsp;</p>
<p>Food allergy was defined as parent report of doctor‐diagnosed cow's milk, soy, egg, wheat, or peanut allergy with or without a positive SPT to the relevant food allergen to capture both IgE and non‐IgE–mediated food allergy phenotypes.&nbsp;</p>
<p>Wheeze was defined as any parental reported wheeze, and number of infections during the first 2 years of life was defined as parent‐reported number of colds with fever lasting at least 3 days to ensure medically significant infections were captured.</p>","<p><b>Sponsor:</b> project grant from the National Health and Medical Research Council. Funding has also been provided by The Royal Women's Hospital Foundation, Melbourne and The Angior Family Foundation, Melbourne.</p>
<p><b>Declaration of interest: </b>Tang M. was a past member of the Nestle Nutrition Institute Medical Advisory Board (Oceania), was a past member of the global scientific advisory board for Danone Nutricia, received speaker fees for seminars sponsored by Danone Nutricia and Nestle Health Sciences, share options/interest in Prota Therapeutics, and was a consultant to Bayer. All other authors have no conflicts of interest to disclose.</p>"
Rautava 2006,2006,PUB,2621324,"<p>Randomised, double-blind, placebo-controlled clinical trial.</p>","<p><b>Inclusion criteria: </b>need for artificial feeding before the age of 2 months. Intervention commenced when the need for artificial feeding arose and the supplemented formula was to be used as the sole infant formula. Not selected on basis of risk of allergy.</p>
<p><br><b>Exclusion criteria: </b>infants with chronic disease.</p>","<p>81 infants randomised to receive infant formula (Enfamil, Mead Johnson Nutritionals, Evansville, IN) supplemented with either:<br><b>Treatment (n = 38): </b>1 x 10<sup>10</sup> colony-forming units of Lactobacillus rhamnosus (Lactobacillus GG, American type culture collection 53103, Valio Ltd., Helsinki, Finland) and Bifidobacterium lactis Bb-12 (Chr. Hansen, Hoersholm, Denmark) daily until the age of 12 months; or</p>
<p><br><b>Control (n = 43): </b>Placebo (microcrystalline cellulose).<br>
 The intervention was commenced when the need for artificial feeding arose and the supplemented formula was to be used as the sole infant formula during the study period.&nbsp;</p>","<p><b>Primary outcomes:</b> effects of probiotic supplementation in reducing the risk of infectious disease in infants devoid of the recommended 6 months of exclusive breast-feeding.</p>
<p><br><b>Other outcomes:</b> clinical examination at 3, 7, and 12 months. Skin prick test performed at ages 7 and 12 months.&nbsp;<br>
 &nbsp;</p>
<p><b>Definitions</b></p>
<p>Atopic eczema: criteria introduced by Hanifin and Rajka (Hanifin 1980).<br>
 Cow’s milk hypersensitivity: Confirmed by double-blind, placebo-controlled cow’s milk challenge. CMA confirmed by SPTs at the ages of 7 and 12 months.</p>","<p><b>Sponsor: </b>funded by the Microbes and Man Research Program, Academy of Finland, and the Sigrid Juselius Foundation.</p>
<p><b>Declaration of interest: </b>not reported.</p>"
Rozé 2012,2012,PUB,22958464,<p>Double-blind randomised controlled trial.&nbsp;</p>,"<p><b>Inclusion criteria:</b> gestational age &gt; 37 weeks, a postnatal age less than 3 days, fed from birth with probiotic- and prebiotic-free infant formula, and without human milk before inclusion. 4 &nbsp;centres participated in the trial (Mother-and-Children Hospital, Nates, France; Children's Hospital Angers, France; Hospital Saint-Vincent de Paul and HospitalSalpetriere, Paris, France).</p>
<p><b>Exclusion criteria: </b>infant presenting a metabolic, nervous, digestive or organic disease able to interfere with study, evidence of cow's milk protein allergy, infant presenting lactose intolerance.</p>","<p><b>Treatment (n = 48): </b>the experimental formula was characterised by the presence of 2 &nbsp;strains of probiotics (Lactobacillus rhamnosus LCS-742 and Bifidobacterium longum subsp infantis M63) and by the addition of prebiotics: 96% galacto-oligosaccharides and 4% short-chain fructo-oligosaccharides. This formula was also enriched with bovinea-lactalbumin, using a native whey protein concentrate with high a-lactalbu-min concentration (34% of soluble proteins) obtained using careful fractionation techniques (ultrafiltration).&nbsp;</p>
<p><b>Control (n = 49):</b> standard infant formula.</p>
<p>The intervention ended at 6 months of age.&nbsp;</p>","<p><b>Primary outcomes: </b>antropometric measurements such as weight, length, BMI, and cranial perimeter. Dermatological examination and scoring atopic dermatitis (SCORAD) index calculation, sleeping time and general well-being using structured interviews.&nbsp;</p>
<p><b>Other outcomes:</b> formula intake for each meal, bowel habits and stool consistency over the 3 d before each visit were also collected from a home diary kept by the parents.&nbsp;</p>
<p><b>Definitions:</b> atopic dermatitis utilised the UK Working Party's diagnostic criteria (William 1994), and SCORAD index was calculated to assess severity.&nbsp;</p>","<p><b>Sponsor:</b> study was supported by grants from Sodliac, France. Ordesa Group provided scientific support.</p>
<p><b>Declaration of interests:</b> J.-C R. and C. D. received consulting fees from Sodilac, France. No other conflicts of interest reported.</p>"
Savino 2010,2010,PUB,2621328,"<p>Randomised, controlled, double-blind study.</p>","<p><b>Inclusion criteria: </b>breastfed infants diagnosed with infantile colic according to modified Wessel’s criteria (Wessel 1954), episodes of fussy crying that lasted 3 hours a day and for 3 days in the 1 week before enrolment.) All were born at term, birth weight: 2500 – 4000 g and aged 2 to 16 weeks.</p>
<p><b>Exclusion criteria: </b>chronic illness or gastrointestinal disorders, any intake of probiotics or antibiotics in the week preceding recruitment, and any formula-feeding.</p>","<p>5 drops, once a day, 30 minutes before the feed in the morning for 21 days:</p>
<p><b>Treatment (n = 25): </b>L reuteri 10<sup>8</sup> live bacteria/day in sunflower oil and medium-chain triglyceride oil.</p>
<p><b>Control (n = 25): </b>placebo (sunflower oil and medium-chain triglyceride oil).</p>","<p><b>Primary outcome:</b> reduction in average crying time to &lt; 3 hours a day on day 21</p>
<p>Other outcomes: the number of responders in each group on days 7, 14, 21. Intestinal microflora of the infants and any adverse effects.</p>
<p><b>Definitions:</b> not given.</p>
<p>Adverse events reported included rhinitis and eczema.</p>
<p>Parents recorded diary. Paediatricians assessed baseline and day 21.</p>","<p><b>Sponsor: </b>funded by BioGaia AB (Stockholm, Sweden).</p>
<p><b>Declaration of interests: </b>not reported.</p>"
Scalabrin 2009,2009,PUB,2621330,"<p>Double-blind, randomised, controlled, parallel, prospective study.</p>","<p><b>Inclusion criteria: </b>eligible infants were healthy, term infants 38 to 42 weeks' gestational age, with birth weight ≥ 2500 g and solely formula-fed at least 24 hours prior to randomisation.</p>
<p><b>Exclusion criteria: </b>history of underlying disease or congenital malformation likely to interfere with normal growth and development or participant evaluation, formula intolerance, weight at 14 days of age &lt; 98% of birth weight, large for gestational age born from a mother diabetic at childbirth, immunodeficiency, fever at randomisation, systemic antibiotic use within 7 days of randomisation, systemic steroid use any time since birth, LGG-supplemented diet any time since birth (including infants breast-fed when mother consumed dietary LGG), and diarrhoea within 24 hours prior to randomisation.</p>","<p>Randomised to receive through 120 days of age:</p>
<p><b>Control (n = 94): </b>extensively hydrolysed (EH) casein formula (Nutramigen LIPIL, Mead Johnson &amp; Company, Evansville, IN);</p>
<p><b>Treatment 1 (n = 94): </b>same formula supplemented with LGG 10<sup>8</sup> cfu per gram of formula powder; or</p>
<p><br><b>Treatment 2 (n = 98): </b>partially hydrolysed whey: casein (60:40) formula supplemented with LGG 10<sup>8</sup> cfu per gram of formula powder.</p>
<p>A subset of infants continued to receive study formula through 150 days of age.</p>
<p>All formulas supplemented with 0.64% arachidonic acid and 0.32% docosahexaenoic acid of total FAs.</p>","<p><b>Primary outcome: </b>to evaluate the effect on growth and tolerance in healthy, term infants from 14 to 120 days of age.</p>
<p><b>Other outcomes:</b> to analyse the incidence of allergies and infections as well as allergic sensitisation and antibody response to routine vaccinations in a subset of infants who received study formula up to 150 days of age. Reported percentages of allergy-related events.</p>
<p><b>Definitions:</b> not given for allergy-related events.</p>
<p>Performed total IgE and specific IgE to cow milk protein by fluorescent EIA. Definitions of allergy-related adverse events not provided in 5 year follow-up study.</p>","<p><b>Sponsor: </b>study was supported by Mead Johnson Nutrition.</p>
<p>Adverse events categorised as allergy-related (EHF, 10%; EHF-LGG, 18%; PHF-LGG, 15%). Data not included in meta-analysis.</p>
<p>Allergy-related adverse event through year 5 included in analysis under childhood incidence.</p>
<p><b>Declaration of interests: </b>DS, CLH and CLB were all employees of Mead Johnson Nutrition at the time of the study. WJ received research support from Mead Johnson Nutrition. No other conflict of interest to disclose.</p>"
Soh 2009,2009,PUB,2621332,"<p>Double-blind, placebo-controlled randomised clinical trial.</p>","<p>Families with a history of allergic disease were recruited from the antenatal clinics.</p>
<p><b>Inclusion criteria: </b>first-degree relative with doctor diagnosis of asthma, allergic rhinitis or eczema and a positive SPT to Dust mites; gestational age &gt;35 weeks; birth weight &gt; 2 kg.</p>
<p><b>Exclusion criteria: </b>no major congenital malformation or illness. Parents who chose to breast-feed exclusively were not considered for the study.</p>","<p>Participants received at least 60 mL (9.26 g) a day of commercially available cow’s milk-based infant formula with:</p>
<p><b>Treatment (n = 127): </b>probiotic supplementation B. longum BL999 (ATCC: BAA-999 designation BB536, Morinaga, Japan) 1x10<sup>7</sup> cfu/g and L. rhamnosus LPR (CGMCC 1.3724) 2 x 10<sup>7</sup> cfu/g initiated within 12 hours for the first 6 months of life; or</p>
<p><b>Control (n = 126):</b> formula without probiotics.</p>
<p>Mothers were free to decide whether to make up the remainder of the baby feeds with either the trial formula, or to supplement with breast milk, or another infant formula. Weaning to solids was allowed at between 4 and 6 months of age according to local practices, but parents were advised to avoid potentially allergenic foods including eggs, shellfish, and peanuts until after the first birthday.&nbsp;</p>","<p><b>Primary outcome:</b> prevention of eczema and allergic sensitisation in the first year of life in Asian infants at risk of allergic disease.</p>
<p><b>Other outcomes</b>: Paediatrician evaluation at 1, 3, 6 and 12 months which involved a detailed history, recording of anthropometric data and clinical examination. Questionnaires are administered at these visits to record clinical disease and environmental exposures. Biweekly phone calls performed for the first 6 months, after which monthly phone contacts were carried out.</p>
<p><b>Definitions</b></p>
<p>Eczema defined as a pruritic rash over the face or extensors with a chronic relapsing course criteria of Hanifin and Rajka (Hanifin 1980), or both physician diagnosed at 12 months, SCORAD index used.</p>
<p>Sensitisation: SPTs and specific IgE at 12 months. A weal &gt; 3 mm in diameter above the negative control was considered positive.&nbsp;</p>","<p><b>Sponsor: </b>National Medical Research Council, Singapore. The study milk formula was sponsored by Nestles, Vevey, Switzerland.</p>
<p>Infant incidence of cow's milk sensitisation/hypersensitivity unable to be included in analysis due to probiotic n = 0 and placebo n = 0. Incidence of atopic disease up to 5 years included in analysis under childhood incidence. Food allergy since year 3 included in analysis under childhood prevalence.</p>
<p><b>Declaration of interests: </b>not reported.</p>"
Taipale 2011,2011,PUB,2621340,"<p>Randomised double-blind, placebo-controlled study.</p>","<p>Newborn 1-month-old infants were recruited.</p>
<p><b>Inclusion criteria:</b> the child was healthy, parents were willing to use the novel slow release pacifier and the child started to receive the tablet before the age of 2 months age.</p>
<p><b>Exclusion criteria:</b> not specified</p>","<p>Children were given 2 &nbsp;probiotic tablets per day via a novel slow-release pacifier. Each tablet contained 5 x 10<sup>9</sup> cfu of BB-12. Until 6 - 8 months of age, children received the tablet via a small pacifier, thereafter via a large pacifier.</p>
<p><b>Treatment (n = 55):</b> probiotic Bifidobacterium animalis BB-12 containing xylitol tablet administered to the infants twice a day (daily dose BB-12 10 x 10<sup>9</sup> cfu) from age 1 – 2 months to 8 months.</p>
<p><b>Control (n = 54):</b> control xylitol tablet.</p>
<p>Exclusive breastfeeding (months - mean (SD)): treatment: 3·4 (1·7); control 3·8 (1·9). The families were encouraged not to use any other pacifier besides the slow-release pacifier twice a week. If families wanted to use a regular pacifier as well, they were offered the pouch-free version of the slow-release pacifier.&nbsp;</p>","<p><b>Primary outcome: </b>reported cumulative incidence of acute respiratory infections and doctor-diagnosed<b> </b>acute otitis media before age of 8 months. Caries occurrence to 4 years.</p>
<p><br><b>Other outcomes</b>: acute infectious diseases to 2 years. Successful intestinal passage of BB-12. Oral microbial colonisation.</p>
<p>Parents reported atopic diseases or allergic sensitisation to 8 months.</p>
<p><b>Definitions: </b>not reported.</p>","<p><b>Sponsor: </b>grants from Emil Aaltonen and Sohlberg Foundations, Finnish Dental Society Apollonia and Finnish Dental Association. Chr. Hansen A/S (Hoersholm, Denmark) donated the BB-12 for the probiotic tablets and helped in carrying out the faecal analysis of BB-12. The tablets were manufactured by Oy Karl Fazer Ab (Vantaa, Finland). The pacifiers manufactured by Mekalasi Oy (Konnevesi, Finland). Neither Hansen, Fazer nor Mekalasi provided financial support.</p>
<p><b>Declaration of interests: </b>T.T had no conflicts of interest. No other conflict of interest reported.</p>"
Taylor 2006,2006,PUB,2621343,"<p>Randomised, double-blind, placebo-controlled trial.</p>","<p><b>Inclusion criteria:</b> pregnant, atopic women. Maternal atopy defined as doctor-diagnosed clinical history of asthma, allergic rhinitis, or eczema plus a positive SPT to 1 or more common allergens.</p>
<p><br><b>Exclusion criteria:</b> women excluded if smoked, had other medical problems or pregnancy complications, delivered before 37 weeks' gestation, or already taking probiotic supplements.</p>","<p><b>Treatment (n = 115): </b>3 x 10<sup>9</sup> / L acidophilus LAVRI-A1 in maltodextrin (Probiomics, Sydney, Australia). Supplements supplied as stable freeze-dried powder, dissolved in 1 to 2 mL sterile water and administered orally daily from birth to 6 months.</p>
<p><br><b>Control (n = 111): </b>maltodextrin alone.</p>
<p><br>
 Intervention commenced within 48 hours of delivery and was given only to the baby, independent of feeding method.</p>","<p><b>Primary outcomes: </b>clinical assessment of atopic dermatitis at 6 and 12 months of age. Incidence of atopic dermatitis, food allergy, and sensitisation at 12 months and 2.5 years of age.r Primary allergy prevention in a population of Australian children at high risk of allergic disease.<br><br><b>Other outcomes:</b> detailed history and examination collected at 12 months and 2.5 years by the same paediatric allergist. Other symptoms based on parental record; all parents who noted (quote:) 'noisy breathing' of any kind were asked to give detail descriptions of this to the paediatrician. Doctor diagnosed gastrointestinal infections were recorded. Assessment of the expression of T-regulatory phenotype.</p>
<p><b>Definitions:&nbsp;</b><br>
 Atopic dermatitis: typical skin lesions responsive to topical steroids. The severity determined using the severity score of atopic dermatitis (SCORAD).<br>
 IgE-mediated food allergy: History of immediate symptoms after contact with or ingestion of food and a positive SPT to the implicated food. Symptoms of acute food allergy include skin reactions (hives, rash or swelling) or respiratory symptoms (cough, wheeze, stridor) or gastrointestinal symptoms (abdominal pain, vomiting, loose stools) or cardiovascular symptoms (collapse).</p>
<p>Asthma: defined as recurrent wheezing (3 or more episodes, at least 1 confirmed by a paediatrician or general practitioner) with evidence of responsiveness to bronchodilator therapy.</p>","<p><b>Sponsor: </b>National Health and Medical Research Council of Australia and Probiomics as an industry partner. The study and all of the analyses were conducted independently of the commercial entity.</p>
<p>Clinical and sensitisation characteristics of the study population at 1 year included in analysis under infant incidence. Clinical and sensitisation at 2.5 years of age included in analysis under childhood incidence. All outcomes described in the 5 year follow-up study refer to ""recent"" symptoms (in the preceding 12 months) unless stated otherwise; thus included in analysis under childhood prevalence.&nbsp;</p>
<p><b>Declaration of interests: </b>not reported.</p>"
Vlieger 2009,2009,PUB,2621350,<p>Randomised controlled trial.</p>,"<p><b>Inclusion criteria: </b>pregnant mothers, who intended to bottle-feed infants born &gt; 37 weeks' gestation and &lt; 7 days at enrolment (N = 159).</p>
<p><b>Exclusion criteria:</b> use of antibiotics in the first week, congenital illnesses or malformations and insufficient Dutch language.</p>","<p>Infants fed to 3 months with a pre-biotic containing starter formula supplemented with L. paracasei ssp paracasei and B. animalis ssp. lactis or the same formula without probiotics. Parents of the first 80 infants who completed the first part of the study were asked to continue the use of the study formula for another 3 months. Parents received the assigned infant formula with written instructions for its preparation and were advised to feed infants ad libitum during the study period. Solid foods were introduced at the age of 4 months.</p>
<p><b>Treatment (n = 69): </b>standard milk-based powder formula with GOS 2.4 g/L with B. animalis 1 x 10<sup>7</sup> cfu/g and L. paracasei 1 x 10<sup>7</sup> cfu/g;</p>
<p><b>Control (n = 64): </b>standard milk-based powder formula with GOS 2.4g/L.</p>","<p><b>Primary outcome: </b>differences in growth parameters at 3 months of age.</p>
<p><b>Other outcomes:</b> differences in growth parameters at the age of 6 months, differences in stool characteristics (consistency and frequency), crying (h/d), the number of upper respiratory tract infections and gastrointestinal tract infections as diagnosed by the parents, the number of antibiotics and visits to the general practitioner. Adverse effects were recorded including vomiting, diarrhoea, constipation, colic and rash or eczema. Recorded in participant diaries.</p>
<p><b>Definitions:</b> definitions not specified. In case of serious adverse events, 1 of the paediatricians was contacted to assess the adverse event.</p>","<p><b>Sponsor: </b>Financed by Friesland Foods, Leeuwarden, The Netherlands.</p>
<p>Did not report data for allergy. Included data for adverse effects which combines rash with eczema.</p>
<p><b>Declaration of interests: </b>J. K and R. t. B were employed by the sponsor (Friesland Foods) at the time of the study. All other authors declared that they had no conflict of interest.&nbsp;</p>"
West 2008,2008,PUB,2621352,"<p>Double-blind, placebo controlled, randomised intervention trial</p>","<p><b>Inclusion criteria: breastfed</b> healthy, term infants (gestational age 37 – 42 weeks), birthweight &gt; 2500 g, vaginally delivered, had no allergic manifestation or medication.</p>
<p><b>Exclusion criteria:</b> atopic manifestation or medication that could affect gut microbiota, i.e. antibiotics, or prior probiotic intake.</p>
<p>Infants at high risk of allergy: probiotic group 66%, placebo 61%.</p>","<p><b>Treatment (n = 89):</b> cereals (containing milk proteins) supplemented with Lactobacillus paracasei F19 (one serving contained 1x10<sup>8</sup> cfu); or</p>
<p><b>Control (n = 90): </b>Same cereals without LF19 from 4 to 13 months of age. The recommended intake was at least 1 &nbsp;serving of cereals daily until 13 months of age.</p>
<p>Parents were asked to avoid feeding the infant other products with probiotics. There was no interference with dietary habits in other respects.</p>","<p><b>Primary outcome: </b>daily breastfeedings as long as the infant was breastfed, and any symptoms from the skin or airway. Any allergy or asthmatic symptoms, doctor's diagnosis and prescription and use of any drug or supplement. Days with infectious symptoms, antibiotic prescriptions and IgG antibody responses to Haemophilus influenza type b (Hib), diphtheria and tetanus vaccines. Reported to 13 months.</p>
<p><b>Definitions:</b></p>
<p>Eczema defined on the basis of questionnaires and diaries as an itchy rash for at least 2 weeks with typical distribution and dry skin or &nbsp;doctors diagnosis of eczema, or both.</p>
<p>Asthma and allergic rhino-conjunctivitis: Only doctor diagnosis of asthma or allergic rhino-conjunctivitis were defined as asthma and allergic rhino-conjunctivitis.</p>
<p>Cow milk protein allergy was diagnosed by a physician by an oral food challenge (blinding not reported).</p>","<p><b>Sponsor:</b> Semper AB, Sweden, Swedish Research Council for Environment, Agricultural Science and Spatial Planning (FORMAS); Swedish Agency for Innovation Systems (VINNOVA); Swedish Research Council, Medicine; the county of Vasterbotten; Ronald McDonald Fund; Swedish Nutrition Foundation; and Oskarfonden.</p>
<p>Follow-up study data at 8 - 9 years of age included in analysis under childhood prevalence.&nbsp;</p>
<p><b>Declaration of interests: </b>none of the researchers had any financial or personal interest in the organisations and companies that sponsored the trial.</p>"
Wickens 2008,2008,MIX,2621355,"<p>Double-blind, randomised placebo-controlled trial.</p>","<p><b>Inclusion criteria: </b>pregnant women - the woman or infant’s biological father had a history of treated for asthma, hay fever, or eczema.</p>
<p><b>Exclusion criteria:</b> planned to move from the study centre during the 2 years study period, delivered &lt; 37 weeks' gestation or had not taken the study probiotic for ≥ 2 weeks pre-birth, already taking probiotic supplements or intended to use these in the child, if infants were &lt; 3rd percentile for weight, had congenital anomalies, infant admission to neonatal unit for more than 48 hours or mother receiving less than 2 weeks of treatment prior to giving birth.</p>","<p>Women were randomised to receive daily supplements of either:</p>
<p><b>Treatment 1 (n = 170): </b>6 x 10<sup>9</sup> cfu/day L. rhamnosus HN001; or</p>
<p><b>Treatment 2 (n = 171): </b>9 x 10<sup>9</sup> cfu/day B. animalis (spp lactis HN019); or</p>
<p><b>Control (n = 171): </b>placebo (dextran, salt and a yeast extract).</p>
<p>Intervention commenced 2 – 5 weeks before delivery, supplementation was continued in the postnatal period for the mother for up to 6 months if breastfeeding and for the baby, independent of feeding methods, for 2 years. Infants started the intervention between 2 and 16 days post-birth, given undiluted to the infant or mixed with water, breast milk, or formula and given via a teaspoon or syringe until solid food was started.</p>
<p>Over 95% breastfed. Mean duration breast feeding 9 months.</p>","<p><b>Primary outcome: </b>eczema prevalence and severity from birth to 2 years. Skin prick test assessed at 24 months.</p>
<p><b>Other outcomes: </b>faecal samples collected soon after birth and at 3, 12, and 24 months of age; safety outcomes and standard morphometric measures, frequency and reason for any adverse effects, antibiotic use by the infants over the treatment period</p>
<p><b>Definitions: </b>eczema prevalence was assessed using a modified version of the UK Working Party’s Diagnostic Criteria (William 1994), for atopic dermatitis at 3, 6, 12, 18 and 24 months via questionnaire and assessment of visible atopic dermatitis. IgE-associated eczema was defined as eczema plus a positive SPT response, and non-IgE associated eczema as eczema plus a negative SPT response.<br>
 Atopy was assessed at 24 months using SPTs and defined as any mean wheal diameter &gt; 3 mm.<br>
 Allergic disease development (eczema, asthma, rhinoconjunctivitis, and atopic sensitisation) was assessed using SPT, total and serum-specific IgE (ssIgE), to age 6 years.</p>","<p><b>Sponsor:</b> Health Research Council of New Zealand and Fonterra Co-operative Group (Auckland, New Zealand).</p>
<p>In this review, infant incidence reports analyses eczema and allergic disease at 2 years of age. Childhood incidence analyses the cumulative prevalence of eczema and allergic disease at 6 years of age. Childhood prevalence analyses the current health outcomes at 6 years. Prevalence of allergic disease measured at 11 years included in analysis under adolescent allergic disease.</p>
<p><b>Declaration of interests: </b>Wickens received research funding from the Health Research Council and Fonterra Co-operative Group. P.N Black has received research funding from the Health Research Council of New Zealand, the Child Health Research Foundation and Boehringer-Ingelheim T. V. Stanley has received research funding from the Health Research Council of New Zealand and Washington Medical Research Foundation. E. Mitchell has received research funding from the Child Health Research Foundation and the National Heart Foundation of New Zealand and has served as trustee in the past year for the Wilson &amp; Sweet Trust and the Child Health Research Foundation. P. Fitzharris has received research funding from the Marsden Fund and the Foundation for Research, Science &amp; Technology. G. W. Tannock has received research support from the Marsden Fund and the Foundation for Research, Science and Technology. G. Purdie has received research funding from the Health Research Council of New Zealand and the Ministry of Health. J. Crane has received research funding from the Health Research Council of New Zealand, Rex Medical and Asthma and Respiratory Foundation of New Zealand, and the National Institute of Environmental Health Sciences.</p>"
